The FCM findings showed that the proportions of CD8+ T cells in the blood and spleen were markedly diminished on the 22nd day post-implantation (p < 0.001, Figures 2B–E), implying that host antitumor immunity was compromised in breast tumor mice. The gene discussed is CD8A; the disease is breast neoplasm.